Human cytomegalovirus glycoprotein B inhibits migration of breast cancer MDA‑MB‑231 cells and impairs TGF‑β/Smad2/3 expression

Yang,Rui; Liang,Jie; Xu,Guo‑Xiong; Ding,Liu‑Mei; Huang,Hong‑Mei; Su,Qi‑Zhu; Yan,Jing; Li,Yun‑Chun

doi:10.3892/ol.2018.8344

Human cytomegalovirus glycoprotein B inhibits migration of breast cancer MDA‑MB‑231 cells and impairs TGF‑β/Smad2/3 expression

Authors:
- Rui Yang
- Jie Liang
- Guo‑Xiong Xu
- Liu‑Mei Ding
- Hong‑Mei Huang
- Qi‑Zhu Su
- Jing Yan
- Yun‑Chun Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Institute of Immunology, University of Heidelberg, Heidelberg D‑69120, Germany, Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: March 23, 2018 https://doi.org/10.3892/ol.2018.8344
Pages: 7730-7738
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is a leading cause of cancer‑associated mortality in females worldwide and evidence suggests that human cytomegalovirus (HCMV) infection may be implicated in the progress of breast cancer. HCMV glycoprotein B (gB) is the most abundant envelope protein and serves an important role in host cell entry. The present study aimed to clarify the role of HCMV gB in breast cancer cells. A HCMV gB construct (UL55) was generated and stable vUL55 gene lentivirus‑transfected MDA‑MB‑231 cells were established. Subsequently, the effect of HCMV gB on the apoptosis and proliferation of MDA‑MB‑231 cells was measured by flow cytometry and Cell Counting Kit‑8 assay. Furthermore, whether HCMV gB may modulate MDA‑MB‑231 cell migration was examined using Transwell and cell scratch assays. In addition, alterations in HCMV gB‑modulated protein levels of transforming growth factor‑β (TGF‑β) and Mothers against decapentaplegic homologs 2/3 (Smad2/3) were detected using western blot analysis. The results indicated that UL55 cDNA was stably transfected into MDA‑MB‑231 cells, and that HCMV gB protein was stably expressed. No significant differences in cell apoptosis and proliferation between transfected (231‑GB‑OE) and negative control (231‑NC) cells were observed, while the rate of cell migration was significantly decreased in the 231‑GB‑OE cells compared with the 231‑NC cells. Additionally, the expression level of TGF‑β and phosphorylation level of Smad2/3 were also decreased in 231‑GB‑OE cells compared with the 231‑NC cells. Although certain previous studies indicated that HCMV infection was associated with breast carcinogenesis, the results of the present study indicate that the envelope protein HCMV gB exhibits no effect on cell apoptosis and proliferation, but inhibits breast cancer cell migration. This may be due to downregulated TGF‑β/Smad signaling. Taken together, these studies may assist in developing anti‑TGF‑β agents that contribute to tumor suppression.

View Figures

View References

1	Britt V: Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and chronic diseaseHuman Cytomegalovirus. Shenk TE and Stinski MF: Springer Berlin Heidelberg; Berlin, Heidelberg: pp. 417–470. 2008, View Article : Google Scholar
2	Colugnati FA, Staras SA, Dollard SC and Cannon MJ: Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 7:12007. View Article : Google Scholar
3	Poole E, McGregor Dallas SR, Colston J, Joseph RS and Sinclair J: Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34⁺ progenitors. J Gen Virol. 92:1539–1549. 2011. View Article : Google Scholar : PubMed/NCBI
4	Revello MG, Furione M, Rognoni V, Arossa A and Gerna G: Cytomegalovirus DNAemia in pregnant women. J Clin Virol. 61:590–592. 2014. View Article : Google Scholar : PubMed/NCBI
5	Fowler KB and Boppana SB: Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 35:226–231. 2006. View Article : Google Scholar : PubMed/NCBI
6	Cannon MJ: Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol. 46 Suppl 4:S6–S10. 2009. View Article : Google Scholar : PubMed/NCBI
7	La Rosa C and Diamond DJ: The immune response to human CMV. Future Virol. 7:279–293. 2012. View Article : Google Scholar : PubMed/NCBI
8	Söderberg-Nauclér C: HCMV microinfections in inflammatory diseases and cancer. J Clin Virol. 41:218–223. 2008. View Article : Google Scholar : PubMed/NCBI
9	Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG II, Rodland K, Wiley S, et al: Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome. J Virol. 78:10960–10966. 2004. View Article : Google Scholar : PubMed/NCBI
10	Feire AL, Roy RM, Manley K and Compton T: The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry. J Virol. 84:10026–10037. 2010. View Article : Google Scholar : PubMed/NCBI
11	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
12	Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 9 Suppl 2:S73–S81. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lawson JS and Heng B: Viruses and breast cancer. Cancers (Basel). 2:752–772. 2010. View Article : Google Scholar : PubMed/NCBI
14	Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, et al: The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. Int J Cancer. 103:226–232. 2003. View Article : Google Scholar : PubMed/NCBI
15	Fagundes CP, Glaser R, Alfano CM, Bennett JM, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE III, Farrar WB, et al: Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immun. 26:394–400. 2012. View Article : Google Scholar : PubMed/NCBI
16	Breathnach O, Donnellan P, Collins D, McNicholas W and Crown J: Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: Case report and review of the literature. Ann Oncol. 10:461–465. 1999. View Article : Google Scholar : PubMed/NCBI
17	Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, Bland KI and Cobbs CS: Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 1:82010. View Article : Google Scholar : PubMed/NCBI
18	Isaacson MK and Compton T: Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 83:3891–3903. 2009. View Article : Google Scholar : PubMed/NCBI
19	Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E and Soroceanu L: HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation. Oncotarget. 5:1091–1100. 2014. View Article : Google Scholar : PubMed/NCBI
20	Costanza B, Umelo IA, Bellier J, Castronovo V and Turtoi A: Stromal Modulators of TGF-β in Cancer. J Clin Med. 6:72017. View Article : Google Scholar
21	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
22	Cao Y, Liu X, Zhang W, Deng X, Zhang H, Liu Y, Chen L, Thompson EA, Townsend CM Jr and Ko TC: TGF-beta repression of Id2 induces apoptosis in gut epithelial cells. Oncogene. 28:1089–1098. 2009. View Article : Google Scholar : PubMed/NCBI
23	Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M and Jackson MW: TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci USA. 108:8668–8673. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ewen ME, Sluss HK, Whitehouse LL and Livingston DM: TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1009–1020. 1993. View Article : Google Scholar : PubMed/NCBI
25	Lebrun JJ: The dual role of TGFβ in human cancer: From tumor suppression to cancer metastasis. ISRN Mol Biol. 2012:3814282012. View Article : Google Scholar : PubMed/NCBI
26	Derynck R, Zhang Y and Feng XH: Transcriptional activators of TGF-beta responses. Cell. 95:737–740. 1998. View Article : Google Scholar : PubMed/NCBI
27	Kang Y: Pro-metastasis function of TGFbeta mediated by the smad pathway. J Cell Biochem. 98:1380–1390. 2006. View Article : Google Scholar : PubMed/NCBI
28	Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et al: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64:7954–7961. 2004. View Article : Google Scholar : PubMed/NCBI
29	Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A and Guise TA: TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
30	Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM and Guise TA: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 4:e68962009. View Article : Google Scholar : PubMed/NCBI
31	Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
32	Massagué J and Gomis RR: The logic of TGFβ signaling. FEBS Lett. 580:2811–2820. 2006. View Article : Google Scholar : PubMed/NCBI
33	Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE and Sampson JH: Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 10:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
34	Scheurer ME, Bondy ML, Aldape KD, Albrecht T and El Zein R: Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116:79–86. 2008. View Article : Google Scholar : PubMed/NCBI
35	Soroceanu L, Akhavan A and Cobbs CS: Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature. 455:391–395. 2008. View Article : Google Scholar : PubMed/NCBI
36	Vanarsdall AL, Wisner TW, Lei H, Kazlauskas A and Johnson DC: PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog. 8:e10029052012. View Article : Google Scholar : PubMed/NCBI
37	Utrera-Barillas D, Valdez-Salazar HA, Gómez-Rangel D, Alvarado-Cabrero I, Aguilera P, Gómez-Delgado A and Ruiz-Tachiquin ME: Is human cytomegalovirus associated with breast cancer progression. Infect Agent Cancer. 8:122013. View Article : Google Scholar : PubMed/NCBI
38	Soroceanu L and Cobbs CS: Is HCMV a tumor promoter? Virus Res. 157:193–203. 2011. View Article : Google Scholar : PubMed/NCBI
39	Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 109:1551–1559. 2002. View Article : Google Scholar : PubMed/NCBI
40	Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR and Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
41	Fynan TM and Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog. 4:493–540. 1993.PubMed/NCBI
42	Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA and Lodish HF: Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA. 94:10669–10674. 1997. View Article : Google Scholar : PubMed/NCBI
43	Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G and Ten Dijke P: Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 29:1351–1361. 2010. View Article : Google Scholar : PubMed/NCBI
44	Iyer S, Wang ZG, Akhtari M, Zhao W and Seth P: Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther. 4:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
45	Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M and Wang XJ: Distinct mechanisms of TGF-beta1–mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 115:1714–1723. 2005. View Article : Google Scholar : PubMed/NCBI
46	Korpal M, Yan J, Lu X, Xu S, Lerit DA and Kang Y: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 15:960–966. 2009. View Article : Google Scholar : PubMed/NCBI
47	Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J and Jin W: Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget. 6:16352–16365. 2015.PubMed/NCBI
48	Burke HG and Heldwein EE: Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11:e10053002015. View Article : Google Scholar : PubMed/NCBI